Real-world effectiveness of post-T-DM1 treatments in HER2-positive metastatic breast cancer: KBCSG-TR1917 observational study.

Norikazu Masuda(Kyoto University), Takahiro Nakayama(University of Shizuoka), Masato Takahashi(National Hospital Organization Hokkaido Medical Center), Nobuyoshi Kittaka(Osaka International Cancer Institute), Takehiko Takata(Daiichi-Sankyo (Japan)), Tetsuhiro Yoshinami, Hiroyuki Yasojima(Osaka National Hospital), Naoko Yamamoto(Disco (japan)), Seung Jin Kim(The University of Osaka), Tomomi Yamada(Osaka University Hospital), Shoichiro Ohtani(Hiroshima Prefectural Rehabilitation Center), Hiroyuki Kurakami(Osaka University Hospital)
Journal of Clinical Oncology
May 20, 2020
10.1200/jco.2020.38.15_suppl.e13020
Cited by 0

Related Papers

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
|Circulation|2017|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Prevention of Infective Endocarditis
|Circulation|2007|2.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k